Corporate America is starting to ration AI, and it’s affecting marketing teams. Axios and The Wall Street Journal report that some enterprises have burned through their entire annual AI budget in just a few months. Others have watched AI spending double or triple with little warning. Continue reading “AI Costs Are Outpacing Marketing Budgets, So How Do You Strategize?”
Artificial Intelligence (AI) is a rapidly growing technology that is used for a wide range of applications across industries. Small, mid-sized, mid-sized, and multinational companies are using AI technology and enhancing their capabilities to work smart in this digital sphere.
Like retail, e-commerce, and manufacturing sectors, AI is gaining prominence across healthcare and pharma sectors. Leveraging the power of this modern Artificial Intelligence in Pharma Industry, the companies are finding innovative ways to resolve some of the significant issues that the pharma sector is facing today.
Yes. AI-powered apps using machine learning, deep learning, predictive analytics, and big data have brought a radical shift in the paradigm of pharma.
Artificial intelligence in Pharmaceutical Industry has the potential to promote innovation, while at the same time increasing productivity and providing better results. In addition, Artificial Intelligence in Pharma Industry offers a value proposition to the companies by creating new and latest business models.
You can observe AI implementation in almost every aspect of the pharmaceutical field. From drug discovery and development to drug manufacturing to supply chain and marketing, AI has its impact. Hence, AI in Pharmaceuticals and Healthcare ensures cost-effectively operations, business efficiency, and hassle-free approvals for new drugs. We learn more about benefits of artificial intelligence in pharmaceutical industry as well.
In this article, we would like to give you a brief overview of the top 10 AI applications in the pharmaceutical sector. These best AI trends & use cases in pharma will let you understand the rapid AI adoption in pharma.
The use of AI in the pharmaceutical industry for the design and development of drugs is increasing. From making small molecules to determining novel biological targets, AI plays a prominent role in drug target identification and validation. It is widely used for multi-target drug innovation and biomarker identification in an efficient way with great accuracy.
A major benefit of the pharma industry is that when AI is administered during drug testing, it minimizes the drug development time. Artificial Intelligence in Pharma Industry will also benefit drug developers to accomplish clinical trials faster and launch their products into the market for use. It leads to a cost and time-saving development process and also makes the innovative drugs available for improving patient care without side effects.
For example, researchers in pharmaceutical can identify and verify novel cancer drugs using data such as longitudinal EMR records (Electronic Medical Records) and other omic data. The AI systems using ML and other data analytics algorithms will extract insights from EMR data and creates the best formulations to design and develop drugs that cure tumors well.
Pharma companies across the globe are using advanced AI-powered tools and ML algorithms to smoothen the drug research, development, and innovation process. These technology tools are designed to detect complex patterns in large datasets. Therefore, AI in pharma industry can be used to resolve problems associated with the research and development process.
This ability to study patterns of various diseases and to determine which composite formulations are best suited for the treatment of specific symptoms of a particular disease is excellent. Pharma industries can invest in the R&D of such drugs that are more likely to treat a disease or medical condition successfully.
Pharmaceutical organizations can use Artificial intelligence to develop medicines Parkinson’s and Alzheimer’s and very rare diseases.
As per Global Genes, it is a fact that almost 95% of rare diseases do not have more drugs to treat and cure faster. However, thanks to the innovative capabilities of AI and ML. The use of AI in the pharmaceutical industry will completely transform this scenario and ensure the most-advanced models for detecting hazardous diseases in the early stage and improve patient outcomes.
Physicians can use advanced machine learning systems to gather, process, and analyze patient health care data. Healthcare professionals across the globe are using deep learning and ML to securely store patient data in the centralized storage system or cloud. It is called Electronic Medical Records (EMR).
Physicians may refer to these health records when they need to understand the effect of a specific genetic trait on a patient’s health or how medicine treats it. Machine Learning systems can use data stored in EMRs to generate real-time estimates for diagnostic purposes and to indicate appropriate treatment for the patient.
As ML technologies are capable of processing and analyzing large amounts of data quickly, they can help speed up the diagnostic process, thereby saving millions of lives.
Pharma companies and healthcare industries are using ML and AI technologies to monitor and assess the spread of infections worldwide. These modern technologies are used for consuming data collected from various resources, analyzing several environmental, biological, and geographical factors on the population health of diverse geographical regions, and deriving data insights to reduce the impact of epidemics in the future.
Artificial intelligence and machine learning models are particularly beneficial for underdeveloped economies that lack medical infrastructure and financial framework to combat the spread of infection.
A good example of this is the ML-based malaria outbreak prediction model, which serves as a warning tool for malaria outbreaks and helps health care providers take the best action to combat it.
It is one of the key pharmaceutical use cases for embracing AI into existing models. The use of AI in the pharmaceutical industry for identifying drug candidates which are under final clinical trials from vast clinical data is on the rise.
Artificial Intelligence in Pharmaceutical Industry will help companies in analyzing thousands of samples in minutes and automatically logs data related to how patients are responding during clinical trials.
Here are a few advantages of using AI in pharma industry for clinical trials:
Hence, the use of artificial intelligence in clinical trials has the potential in fastening clinical trials and introduce the safest drugs into the market. It is also one of the top use cases for Machine Learning in Pharma. Speech analysis and real-time patient and drug monitoring activities will be done accurately using ML, deep learning, and natural language processing technologies.
The adoption of AI in Pharmaceuticals and Healthcare is increasing at a rapid pace for identifying the right amount of drug intake to ensure the safety of drug consumers. AI technology will monitor patients during clinical trials and suggest the right amount of dosage at regular intervals.
These are all key pharmaceutical use Cases for Embracing AI. AI in Pharmaceuticals and Healthcare will definitely accelerate automation in processes and drive more accuracy than ever before.
These AI trends & use cases in pharma will assist drug development and healthcare companies in ensuring efficacy across end-to-end production lines and delivering top-notch performance in front of the FDA.
The scope of Artificial intelligence and machine learning in the Pharma industry looks very promising in the future. AI opportunities for pharma companies are unmeasurable.
The use of AI applications in pharma will ensure operational excellence across drug structure design, drug development processes, selecting patients for clinical trials, monitoring drug performance, identifying proper dosage, etc.
Are you looking to hire an AI Development Company for your AI application?
Our AI consultants and developers will guide you on the right path!
There’s a moment in every technology cycle when a tool stops being a competitive edge and starts becoming essential to work. For AI in B2B marketing, that time has arrived. Continue reading “74% of Professionals Call AI Essential But Their Companies Lag Behind”
Kevin Roose is an award-winning technology columnist for The New York Times and the best-selling author of three books, “Futureproof,” “Young Money,” and “The Unlikely Disciple.” His column, The Shift, examines the intersection of tech, business, and culture. Continue reading “The AGI Chronicles [MAICON 2026]”
Today, we are thrilled to announce a monumental milestone in Clarifai’s journey: we have entered into an agreement for Nebius (NASDAQ: NBIS), the AI cloud company, to license our core engineering and research talent and license our AI inference and compute orchestration intellectual property.
For over a decade, we at Clarifai were obsessed with building the ultimate software layer for AI. As the industry’s fastest AI inference and reasoning platform on GPUs, we focused on system-level inference optimization, empowering developers with seamless compute orchestration to run models cost-effectively. Now, we take our technology to the biggest stage possible.
When looking at the future of AI, it is obvious that delivering efficient execution at scale requires a seamless marriage of model optimization, software design and compute orchestration.
Here is why our team is incredibly energized about this transition:
Our licensing agreement is set to strengthen directly the Nebius Token Factory to create a complete, full-stack inference platform. While Nebius’s recent acquisition of Eigen AI focuses on optimizing at the model level, Clarifai optimizes the system, creating the end-to-end infrastructure required to run complex AI models reliably in production.
Our performance optimization will compete with the industry’s highest speeds, enhance compute orchestration to open the cloud to a broader customer base and push the boundaries of Nebus Token Factory.
As part of this transition, I am incredibly proud to share that I will be taking on the role of SVP Research at Nebius. I will be leading a dedicated new research unit focused on frontier AI innovations, including agentic reasoning, multimodal world models, token efficiency, and long-term memory.
The future of AI—from advanced agentic systems to frontier models—depends entirely on the infrastructure powering it. By bringing together our proven expertise in training state of the art AI models with Nebius’s elite team, we are uniquely positioned to become one of the strongest combined AI teams on the planet.
The scope of the agreement is limited to Clarifai’s modern AI inference and compute orchestration technology. It does not include Clarifai’s legacy computer vision models. The Clarifai brand or trademark, or any intellectual property, products, services, or commercial arrangements associated with Clarifai’s US government and defense programs.
As we embark on this new chapter, I want to take a moment to thank the incredible team at Clarifai. Building this platform for over a decade was an amazing journey only made possible by the dedication, brilliance, and hard work of every single person who was a part of this company. While not everyone will be transitioning with us to Nebius, I am profoundly grateful for the foundational contributions each of you has made. Your work has left an indelible mark on the AI industry.
I want to personally thank you for everything you have done to get us to this milestone.
We also want to thank our amazing community, partners, and customers who have supported Clarifai’s vision from the very beginning. We can’t wait to embark on this rocket ship and build the ultimate foundation for the next decade of AI inference.
Onward!
Matthew Zeiler, Ph.D. Founder and CEO, Clarifai
Most healthcare AI conversations stall in the same place. The operations leader knows the problem. The case for doing something is clear. The question that does not have a clean answer is: what does the first 90 days actually look like?
This is the roadmap USM Business Systems uses with mid-market health systems, specialty pharmacy operators, and pharma and CRO organizations who are moving from interest to implementation. It is designed for organizations that do not have 18 months or a seven-figure platform budget. It is designed for teams that want to start, measure, and expand.
A 90-day AI roadmap for healthcare operations is only as good as the three inputs that shape it. Get these clear before any build decision is made.
Every mid-market healthcare operation has multiple AI opportunities. The teams that move fastest pick one. The one with the most direct and measurable cost attached.
Prior authorization backlog and approval cycle time. Pharmacy intake processing speed. Denial rate on a specific service line or payer. Pick the one where someone can tell you what a miss costs in dollars, write-offs, or delayed patient starts. That is where you start.
The roadmap is shaped by what you can connect the agent to. EHR API access. Clearinghouse transaction feeds. Payer portal data exports. Pharmacy management system integrations. You do not need all of these to start. You need the ones relevant to the problem you are solving.
A two-week scoping engagement with USM maps your data access reality and builds the agent architecture around what exists, not what would be ideal.
Before build begins, define what success looks like at 90 days. A number. Prior auth turnaround reduced from 8 days to 48 hours. Denial rate on oncology claims reduced from 14% to 6%. Pharmacy intake processing recovered from next-day manual review to same-hour automated triage.
That metric drives scope. It also drives the conversation about whether to expand.
This is a working session, not a sales process.
At the end of day 14, you have an architecture document, a build scope, a timeline, a compliance review, and a defined metric.
The build phase runs in two tracks simultaneously.
Track one is data integration. The agent connects to your existing systems and begins ingesting live data through HIPAA-compliant pathways. This phase surfaces the data quality issues that need to be addressed before the agent can produce reliable outputs. Those issues are resolved here, not discovered after go-live.
Track two is agent logic development. The monitoring rules, the exception thresholds, the scenario modeling logic, and the reporting templates are built and tested against real data from your operation.
By day 45, a test version of the agent is running against your data. The clinical operations team begins evaluating outputs. Feedback shapes the final configuration before go-live.
Go-live is a transition, not a launch event. The agent moves from test to production. The team begins using it as the primary source for the problem it was built to solve.
The measurement cycle starts at day one of production. The success metric defined in scoping is tracked weekly. By the end of day 90, you have six weeks of live data showing the impact on authorization turnaround, denial rates, intake processing speed, or whatever metric was set.
That six weeks of measurement data is what drives the conversation about what to build next.
The teams that get the most out of healthcare AI deploy on one problem, measure it, and expand. The common expansion paths after a successful first deployment:
Each expansion is scoped and built with the same 8–12 week discipline. The architecture from the first deployment is designed to support expansion from the start.
The healthcare operations leaders who move fastest on AI pick one problem, run a contained build, and measure it. That is the entire edge.
For qualified healthcare operations engagements, USM fronts the proof-of-concept cost. You identify the problem. We scope and build the initial deployment. You measure the output before making a larger commitment.
The engagement starts with a scoping conversation. If the architecture is sound and the ROI case is clear, we move to build within two weeks.
Ready to scope your first healthcare AI deployment? Start with a 30-minute conversation at usmsystems.com. No pitch deck. Just the architecture conversation.
In this fourth session of the Let’s Talk Knowledge Engineering series, Ben Taylor, Rainbird CTO and co-founder, is joined by members of the Rainbird Knowledge Engineering team, including Lewis Leeds, Lucie Hunt, and Ellie Young, for a live panel discussion focused on the realities of the role in practice.
Together, they share first-hand perspectives on how knowledge engineering projects run day to day, how teams work with subject matter experts to capture and structure expertise, and what surprised them when they first entered the field. The session offers an open and practical view of the discipline, covering everything from elicitation and modelling to testing, maintenance, and the evolving role of Knowledge Engineers alongside modern AI approaches.
You can register for the remaining session in the series here or watch past episodes here.
What you’ll learn
Resources shared in the webinar
Every leader trying to navigate AI faces a similar challenge: How to keep pace with a technology moving faster than our institutions, our policies, and our economic framework.
Continue reading “How AI Can Build a Future that Works for Everyone [MAICON 2026]”
The question we get most often in the first conversation with a healthcare operations leader is not ‘can AI do this?’ It is ‘what exactly does it do, and what does it replace?’
That is the right question. And the answer is specific.
A clinical operations AI agent replaces the manual work that happens before the judgment. The reconciling, the assembling, the waiting-for-the-report work that consumes hours every week and still produces outputs that are stale by the time anyone reads them.
USM Business Systems builds clinical operations AI agents for mid-market health systems, specialty pharmacy groups, and pharma and CRO organizations. Here is what those agents actually do.
Most clinical operations teams reconcile data manually. Prior auth statuses from payer portals. Prescription intake status from the pharmacy management system. Patient eligibility from the clearinghouse. Claim status from the EHR billing module. All of it arriving at different cadences, in different formats, from different systems.
The agent handles all of that continuously. Authorization statuses update when payer decisions come through. Prescription intake positions update as processing completes. Eligibility verification updates as clearinghouse responses arrive. The team opens the dashboard and the picture is current.
The most expensive clinical operations problems are the ones nobody noticed until they became denials or delays. A prior auth that has been sitting in a payer queue for eight days. A specialty drug with a procurement constraint that is not visible in the formulary system. A patient eligibility issue that will generate a claim denial 30 days from now.
The agent monitors the operation continuously and surfaces exceptions automatically. It does not wait for the weekly review. It flags the situation when the threshold is crossed.
When a clinical operations problem occurs, the investigation typically takes longer than the resolution. Where did the breakdown start? Which payer? Which authorization type? Which upstream data signal was the leading indicator?
The agent traces disruptions backward through the data and presents the cause with supporting evidence. The operations director does not spend Monday morning running the investigation. They receive the analysis and move to the response.
Healthcare operations decisions under uncertainty require modeling. What happens to authorization approval rates if Payer A changes their criteria next quarter? What does adding a second specialty drug to the formulary do to procurement timelines and patient wait times? What is the revenue exposure if denial rates on this service line hold at the current pace through Q3?
Historically, running those scenarios required an analyst, a spreadsheet, and time that is usually not available before the decision needs to be made.
The agent accepts plain-language questions and returns modeled answers. The revenue cycle director or pharmacy director asks the question and gets the output in minutes. The decision is made with the modeling, not in spite of the absence of it.
Weekly ops reviews, payer scorecards, and executive summaries do not disappear when a clinical operations agent is deployed. What changes is who builds them.
The agent generates those reports automatically, from the live data it is already reconciling. The narrative is written. The tables are populated. The anomalies are flagged.
The clinical operations team does not spend Thursday building Friday’s report. Reporting becomes a byproduct of operations, not a project with a deadline.
The teams that get the most out of clinical operations AI identify one specific problem and run a contained build on it first.
USM scopes every healthcare AI engagement in two weeks. We identify the one or two problems with the clearest ROI and the fastest measurement cycle. We build to that scope. We measure from week one.
Most first deployments are live within 8–12 weeks. The team starts using the output before the quarter is out.
Request a 30-minute Clinical Operations AI walkthrough at usmsystems.com. See the live system, not the slide deck.
Most mid-market healthcare operations leaders have already looked at the major platforms. Epic Cheers. Veradigm. Health Catalyst. They have seen the demos. The capabilities look right. The implementation timelines look long, the price tags look like health system budget, and the fit to their actual data environment looks questionable.
The question becomes: what do you actually build, and what do you buy?
USM Business Systems works with mid-market health systems, specialty pharmacy groups, and pharma/CRO organizations to answer exactly that question. What follows is the framework we use.
The first thing that determines your stack is your data environment, not your budget or your timeline.
If your EHR is current, your prior auth workflow is structured, and your payer data is clean and reliable, you have more platform options. If you are managing two EHR’s from an acquisition, a prior auth process that routes through fax, and payer status updates that live in coordinator inboxes, most platforms will underdeliver.
The reason is straightforward. Enterprise healthcare AI platforms are calibrated to enterprise data infrastructure. Mid-market infrastructure is almost always messier. That is not a failure of the operations team. It is a function of how mid-market healthcare organizations grow.
A platform that assumes a clean data model will give you clean outputs in the demo and noisy outputs in production. The question to ask in every vendor evaluation: what does this platform do with dirty data?
Off-the-shelf healthcare AI platforms are strong when:
For organizations where those conditions hold, a platform makes sense. The vendor handles model maintenance, the infrastructure, and the regulatory roadmap.
A custom healthcare AI agent is the right architecture when:
The tradeoff is that custom builds require an engineering partner with healthcare domain understanding. Generic AI development shops can build the software. They often miss the operational and compliance logic that determines whether the outputs are actually usable in a regulated environment.
USM uses a three-question filter with every new healthcare engagement:
First: Is the problem standard or specific? A prior authorization workload at a specialty pharmacy managing oncology patients across 15 payers is not a standard problem. A platform built for median-case prior auth will give median results.
Second: How clean is the underlying data? If significant data normalization is required before a platform can run, that cleanup cost goes into the build-vs-buy calculation. Custom agents can be built to work with imperfect, fragmented data.
Third: What is the decision speed requirement? If you need operational improvements in 8–12 weeks, a platform with a 12-month implementation is not the right answer regardless of long-term fit.
Most mid-market healthcare operations teams land in a hybrid. They buy infrastructure at the commodity layer (EHR, practice management, claims processing) and build custom at the intelligence layer: the agent that sits on top and synthesizes signals into decisions.
That is the architecture USM – one of the best ai app development companies in USA, deploys. The agent connects to existing systems via HL7, FHIR API, or structured data export. It does not require an EHR migration or a claims system replacement. It meets the data where it is and builds the visibility and decision layer on top.
Deployment timeline: 8–12 weeks from scoping to first output. ROI measurement starts at week one.
USM offers a no-cost architecture consultation for healthcare operations leaders evaluating AI options. Book a session at usmsystems.com.
![The AGI Chronicles [MAICON 2026]](https://www.fazb.com.sa/wp-content/uploads/2026/05/The-AGI-Chronicles-MAICON-2026.png)
![How AI Can Build a Future that Works for Everyone [MAICON 2026]](https://www.fazb.com.sa/wp-content/uploads/2026/05/How-AI-Can-Build-a-Future-that-Works-for-Everyone.png)
